Standard Operating Procedure for the Good Manufacturing Practice-Compliant Production of Human Endometrial Stem Cells for Multiple Sclerosis Publisher Pubmed



Ebrahimibarough S¹ ; Ai J¹ ; Payab M² ; Alavimoghadam S³ ; Shokati A¹ ; Aghayan HR³ ; Larijani B⁴ ; Arjmand B^{3, 5} Show Affiliations
Source: Methods in Molecular Biology Published:2021

Abstract

Multiple sclerosis (MS) is the most common cause of neurological diseases. Although, there are some effective medications with regulatory approval for treating MS, they are only partially effective and cannot promote repairing of tissue damage directly which occurs in the central nervous system. Therefore, there is an essential need to develop novel therapeutic approaches for neuroprotection or repairing damaged tissue in MS. Accordingly, cell-based therapies as a novel therapeutic strategy have opened a new horizon in treatment of MS. Each setting in cell therapy has potential benefits. Human endometrial stem cells as an invaluable source for cell therapy have introduced treatment for MS. In this respect, good manufacturing practice (GMP) has a pivotal role in clinical production of stem cells. This chapter tries to describe the protocol of GMP-grade endometrial stem cells for treatment of MS. © 2020, Springer Science+Business Media New York.